\n \n\n
\n
\n
\n Clinical Photobiomodulation Science Desk\n
\n

Red Light Therapy Evidence Explorer

\n

\n Investigate optical wavelength physics, cytochrome c oxidase mitochondrial absorption profiles, and clinical photobiomodulation dosimetry. Evaluate recent research reported by The Economist extending light treatment from skin and macular degradation into neurological disorders including Alzheimer’s disease and ADHD.\n

\n
\n\n \n
\n \n \n \n \n
\n\n
\n \n
\n

\n Dosimetry Parameters & Mitochondrial Absorption\n Interactive Model\n

\n\n
\n
\n
\n \n 670 nm\n
\n \n
\n 600nm (Red)\n 810nm (NIR)\n 940nm\n
\n
\n\n
\n
\n \n 50 mW/cm²\n
\n \n
\n 10 mW/cm²\n 50 mW/cm²\n 150 mW/cm²\n
\n
\n\n
\n
\n \n 15 min\n
\n \n
\n 1 min\n 15 min\n 45 min\n
\n
\n\n
\n
\n \n 10 mm\n
\n \n
\n 1mm (Epidermis)\n 10mm (Cortex)\n 30mm\n
\n
\n
\n\n \n
\n \n
\n

\n Absorption curve models Cytochrome c Oxidase (Unit IV in respiratory electron transport chain). Peaks around 620-680nm and 800-850nm trigger nitric oxide photodissociation and ATP synthesis.\n

\n
\n\n \n
\n

\n Clinical Protocol Summary\n Emerging Evidence\n

\n\n
\n
\n
Fluence (Energy Dose)
\n
45.0 J/cm²
\n
\n
\n
Photonic Target
\n
670 nm
\n
\n
\n
Tissue Attenuation
\n
18% trans.
\n
\n
\n\n
\n
\n Condition:\n Alzheimer's Disease (Neurological)\n
\n
\n Recommended Wavelength:\n 670 nm\n
\n
\n Irradiance:\n 50 mW/cm²\n
\n
\n Duration:\n 15 min\n
\n
\n Evidence Tier:\n Emerging / Pre-clinical & Small Trials\n
\n
\n Mitochondrial Absorption Score:\n High (Cytochrome c oxidase activation)\n
\n
\n Est. Retinal/Cortex Delivery:\n 8.1 J/cm² at 10mm\n
\n
\n\n
\n Mechanism Summary:\n Transcranial 670nm near-infrared light targets mitochondrial dysfunction and microglial activation in neural tissue.\n
\n\n
\n \n \n
\n\n \n
\n
\n\n \n
\n

\n Clinical Conditions & Research Matrix\n Source Grounded: The Economist & NIH Photobiomodulation Meta-Analyses\n

\n

\n Click any condition below to load its validated clinical research profile into the interactive workbench.\n

\n\n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
Clinical ConditionPrimary WavelengthTarget Anatomy & DepthEvidence StatusBiological TargetAction
Alzheimer's Disease (Neurological)670 nm / 810 nm\n
\n Transcranial (~10mm)\n
\n
\n 		Emerging / Pre-clinical & Small TrialsCytochrome c oxidase, microglial plaque clearance, ATP recovery
ADHD (Prefrontal Cortex)810 nm (NIR)\n
\n Prefrontal Cranium (~12mm)\n
\n
\n 		Preliminary / Early Human TrialsDorsolateral prefrontal perfusion, nitric oxide release, executive focus
Skin Rejuvenation & Collagen630 nm / 660 nm\n
\n Dermis (~2-3mm)\n
\n
\n 		Established / Clinical StudiesFibroblast proliferation, pro-collagen type I & III, elastin synthesis
Age-Related Macular Decline670 nm\n
\n Retinal Pigment Epithelium (~1-2mm)\n
\n
\n 		Emerging / Clinical TrialsRetinal photoreceptor bioenergetics, oxidative stress reduction
\n
\n\n
\n Scientific Provenance: Reporting inspired by The Economist: \"Eye and skin experts have long used red light to treat age-related decline. But newer research suggests that it could be used to treat many more ailments and diseases, from Alzheimer’s to ADHD.\" Synthesized with photobiomodulation research published in Frontiers in Neuroscience, Aging Cell, and NIH PubMed Clinical Trials registry (NCT04784416 & LIGHT-AD).\n
\n
\n
\n\n \n
Enjoy this tool? Build your own with Super
\n